<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Radiol Exp</journal-id><journal-id journal-id-type="iso-abbrev">Eur Radiol Exp</journal-id><journal-title-group><journal-title>European Radiology Experimental</journal-title></journal-title-group><issn pub-type="epub">2509-9280</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410512</article-id><article-id pub-id-type="pmc">PMC12102402</article-id>
<article-id pub-id-type="publisher-id">589</article-id><article-id pub-id-type="doi">10.1186/s41747-025-00589-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>7-T MRI-based surrogate for histopathology examination of liver fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dana</surname><given-names>J&#x000e9;r&#x000e9;my</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fattori</surname><given-names>Antonin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Po</surname><given-names>Chrystelle</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Beaufr&#x000e8;re</surname><given-names>Aur&#x000e9;lie</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Vilgrain</surname><given-names>Val&#x000e9;rie</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Paradis</surname><given-names>Val&#x000e9;rie</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Pessaux</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Baumert</surname><given-names>Thomas F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Gallix</surname><given-names>Beno&#x000ee;t</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0608-2353</contrib-id><name><surname>Venkatasamy</surname><given-names>A&#x000ef;na</given-names></name><address><email>aina.vnkt@gmail.com</email></address><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pg6eq24</institution-id><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>Universit&#x000e9; de Strasbourg, Inserm, UMRS 1110, </institution><institution>Institute for Translational Medicine and Liver Disease, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053694011</institution-id><institution-id institution-id-type="GRID">grid.480511.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 8337 1471</institution-id><institution>Institute of Image-Guided Surgery - IHU Strasbourg, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01pxwe438</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution>Department of Diagnostic Radiology, </institution><institution>McGill University, </institution></institution-wrap>Montreal, Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cpxjv19</institution-id><institution-id institution-id-type="GRID">grid.63984.30</institution-id><institution-id institution-id-type="ISNI">0000 0000 9064 4811</institution-id><institution>Augmented Intelligence &#x00026; Precision Health Laboratory (AIPHL), </institution><institution>Research Institute of the McGill University Health Centre, </institution></institution-wrap>Montreal, Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bckew43</institution-id><institution-id institution-id-type="GRID">grid.412220.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 138X</institution-id><institution>D&#x000e9;partement de Pathologie, </institution><institution>H&#x000f4;pitaux Universitaires de Strasbourg, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pg6eq24</institution-id><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>ICube UMR 7357, Universit&#x000e9; de Strasbourg/CNRS, </institution><institution>F&#x000e9;d&#x000e9;ration de M&#x000e9;decine Translationnelle de Strasbourg, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05f82e368</institution-id><institution-id institution-id-type="GRID">grid.508487.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 7885 7602</institution-id><institution>D&#x000e9;partement de Pathologie, H&#x000f4;pital Beaujon, FHU MOSAIC, </institution><institution>Universit&#x000e9; Paris Cit&#x000e9;, </institution></institution-wrap>Paris, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05f82e368</institution-id><institution-id institution-id-type="GRID">grid.508487.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 7885 7602</institution-id><institution>D&#x000e9;partement de Radiologie, H&#x000f4;pital Beaujon, </institution><institution>Universit&#x000e9; Paris Cit&#x000e9;, </institution></institution-wrap>Paris, France </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bckew43</institution-id><institution-id institution-id-type="GRID">grid.412220.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 138X</institution-id><institution>Service de Chirurgie Visc&#x000e9;rale et Digestive, Nouvel H&#x000f4;pital Civil, </institution><institution>H&#x000f4;pitaux Universitaires de Strasbourg, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bckew43</institution-id><institution-id institution-id-type="GRID">grid.412220.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 138X</institution-id><institution>P&#x000f4;le H&#x000e9;pato-digestif, Service d&#x02019;H&#x000e9;patogastroenterologie, </institution><institution>H&#x000f4;pitaux Universitaires de Strasbourg, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wttst55</institution-id><institution-id institution-id-type="GRID">grid.413695.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2201 521X</institution-id><institution>D&#x000e9;partement de Radiologie, </institution><institution>H&#x000f4;pital Am&#x000e9;ricain de Paris, </institution></institution-wrap>Paris, France </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kvxyf05</institution-id><institution-id institution-id-type="GRID">grid.5328.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2186 3954</institution-id><institution>Inria, </institution><institution>Institut national de recherche en sciences et technologies du num&#x000e9;rique, </institution></institution-wrap>Paris, France </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000000121866389</institution-id><institution>Plateforme Imageries du Vivant, Universit&#x000e9; de Paris, PARCC, </institution><institution>INSERM, </institution></institution-wrap>Paris, France </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03vzbgh69</institution-id><institution-id institution-id-type="GRID">grid.7708.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9428 7911</institution-id><institution>Department of Radiology&#x02013;Medical Physics, </institution><institution>University Hospital Freiburg, </institution></institution-wrap>Freiburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>9</volume><elocation-id>54</elocation-id><history><date date-type="received"><day>5</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To demonstrate that 7-T magnetic resonance imaging (MRI) provides a surrogate for histopathology of fresh <italic>ex vivo</italic> liver tissue, using the case study of liver fibrosis.</p></sec><sec><title>Methods</title><p id="Par2">We prospectively enrolled 20 patients undergoing surgical liver resection between November 2021 and April 2023. Each <italic>ex vivo</italic> fresh liver tissue specimen (~&#x02009;1&#x02009;cm<sup>3</sup>) was sectioned in half. The first half, stained using Masson&#x02019;s Trichrome and Perls, was assessed by three pathologists using the METAVIR score (reference standard). The second half was imaged with 7-T MRI using a cryoprobe (fat-suppressed T2-weighted turbo/fast spin-echo sequence, spatial resolution 75 &#x000d7; 75 &#x000d7; 200 &#x000b5;m<sup>3</sup>) and assessed by three radiologists and the same three pathologists, using a newly developed MRI-METAVIR score.</p></sec><sec><title>Results</title><p id="Par3">Five patients were excluded from the final analysis (one patient due to poor specimen quality, two due to surgery cancellation, and two previously published used for reader training). Of the remaining 15 patients, 10 (67%) presented with chronic liver diseases and 8/15 (53%) with advanced (F3 or F4) fibrosis. Radiologists achieved 88% sensitivity, 100% specificity, 93% accuracy (95% confidence interval 68&#x02013;100%) and 0.94 Harrell&#x02019;s c-index (0.86&#x02013;1.00). Pathologists achieved 88% sensitivity, 86% specificity, 87% accuracy (60&#x02013;98%) and 0.87 Harrell&#x02019;s c-index (0.74&#x02013;0.99). There were no statistically significant differences between MRI-based and pathologic reference standard stage (<italic>p &#x02265;</italic> 0.655).</p></sec><sec><title>Conclusion</title><p id="Par4">With an in-plane spatial resolution of ~ 75 &#x000d7; 75 &#x000b5;m<sup>2</sup>, MRI paralleled low-magnification histology, enabling the assessment of micro-architectural liver changes, and provided a surrogate for histopathology examination of fresh <italic>ex vivo</italic> liver tissue samples at a microscopic level.</p></sec><sec><title>Relevance statement</title><p id="Par5">7-T MRI provides a surrogate for histopathology visualisation of fresh <italic>ex vivo</italic> liver tissue, opening new research perspectives for clinical high-field MRI of the liver.</p></sec><sec><title>Key Points</title><p id="Par6">
<list list-type="bullet"><list-item><p id="Par7">Using the newly developed MRI-METAVIR score, 7-T MRI data strongly correlated with histopathology, achieving excellent agreement and accuracy.</p></list-item><list-item><p id="Par8">7-T MRI accurately differentiated advanced from minimal liver fibrosis.</p></list-item><list-item><p id="Par9">7-T MRI visualises liver micro-architecture, enabling pathology-like, noninvasive three-dimensional imaging.</p></list-item></list>
</p></sec><sec><title>Graphical Abstract</title><p id="Par10">
<graphic position="anchor" xlink:href="41747_2025_589_Figa_HTML" id="d33e433"/>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis</kwd><kwd>Histopathology</kwd><kwd>Liver diseases</kwd><kwd>Liver fibrosis</kwd><kwd>Magnetic resonance imaging</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004097</institution-id><institution>Fondation ARC pour la Recherche sur le Cancer</institution></institution-wrap></funding-source><award-id>TheraHCC2.0 IHU201901299</award-id><award-id>references ANR-10-IAHU-02</award-id><award-id>ANR-10-LABX-0028</award-id><principal-award-recipient><name><surname>Baumert</surname><given-names>Thomas F.</given-names></name><name><surname>Gallix</surname><given-names>Beno&#x000ee;t</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019180</institution-id><institution>HORIZON EUROPE European Research Council</institution></institution-wrap></funding-source><award-id>ERC-AdG-2020-FIBCAN #101021417</award-id><principal-award-recipient><name><surname>Baumert</surname><given-names>Thomas F.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; European Society of Radiology (ESR) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">Histopathological examination, the standard of care for tissue analysis, requires intricate technical processes for tissue preparation, which inevitably delay the availability of results by at least 12&#x02009;h following tissue sampling, rendering it unsuitable for intraoperative decision-making [<xref ref-type="bibr" rid="CR1">1</xref>]. Extemporaneous histopathological examination, which employs an alternative technical procedure, enables a reduction in turnaround time, yielding preliminary results in less than 30&#x02009;min [<xref ref-type="bibr" rid="CR2">2</xref>]. However, these alternative procedures involve a freezing step and are responsible for tissue alterations such as morphological artefacts and sample exhaustion. Additionally, histopathological examination of liver biopsies is also prone to sampling errors [<xref ref-type="bibr" rid="CR3">3</xref>] and/or inter-reader variability [<xref ref-type="bibr" rid="CR4">4</xref>]. Although rare, liver biopsies are invasive with risks of bleeding complications [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par15">High-field magnetic resonance imaging (MRI), with recent improvements such as radiofrequency coils, sequence optimisation, and imaging postprocessing [<xref ref-type="bibr" rid="CR6">6</xref>], is now able to reach a very high spatial resolution, approximating that of histology (<italic>i.e</italic>., &#x0003c;&#x02009;100&#x02009;&#x000b5;m, compared to ~&#x02009;1&#x02009;mm for clinical MRI) and appears as a promising tool to image fresh <italic>ex vivo</italic> tissues [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Several studies reported the potential of high-field MRI for a pathology-like analysis of resected breast and lymphatic tissue on fresh <italic>ex vivo</italic> tissue samples [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Similarly, the potential of this tool to provide pathology-like images was previously confirmed on two <italic>ex vivo</italic> liver samples [<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, MRI is a noninvasive imaging modality, without the incompressible tissue processing time required for histology, with limited tissue preparation. High-field MRI appears as a promising &#x0201c;missing link&#x0201d; between conventional imaging and histology.</p><p id="Par16">Liver fibrosis is characterised by the accumulation of extracellular matrix proteins caused by sustained liver insults. It is the inevitable consequence of all progressive chronic liver disease, ultimately leading to cirrhosis with complications such as hepatocellular carcinoma and portal hypertension. Liver fibrosis appears as an appropriate model for exploring high-resolution MRI because of the existence of widely validated histological classifications of liver fibrosis, with low subjectivity, such as the METAVIR system score used to classify the liver tissue on Masson&#x02019;s trichrome-stained sections into five levels, from F0 to F4 [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par17">This study aims to demonstrate that high-field MRI provides an accurate surrogate for histopathology examination of fresh <italic>ex vivo</italic> tissue using the case study of liver fibrosis on surgical liver samples.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par18">This prospective project was approved by the Research Ethics Board (Protocol RIPH2, LivMod N&#x000b0;IDRCB 2019-A00738-49 ClinicalTrial NCT04690972) and followed ethical principles of the Declaration of Helsinki. All patients provided written informed consent.</p><sec id="Sec3"><title>Study design</title><p id="Par19">This prospective study enrolled twenty patients aged &#x0003e; 18 years, who underwent surgical liver resection between November 2021 and April 2023. The overall study workflow is presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. We used <italic>ex vivo</italic> fresh liver tissue (~&#x02009;1&#x02009;cm<sup>3</sup>) from surgically resected livers. Each fragment was sectioned in half, and the sections were identified, so that the MRI acquisition plane was as close as possible to the histological one. We imaged the first half, placed in Fluorinert&#x02122; Electronic Liquid FC40 (Sigma-Aldrich, Overijse, Belgium), a nonconductive, thermally and chemically stable fluid without <sup>1</sup>H signal, using a 7-T MRI system with a cryoprobe (Bruker BioSpin, Rheinstetten, Germany). T2-weighted fat-suppressed turbo/fast spin-echo images were acquired with a rapid imaging with refocused echoes (RARE) sequence, whose parameters are summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The cryoprobe technology employs cryogenically cooled radiofrequency coils and amplifiers cooled by a closed-cycle refrigeration system, allowing the reduction of electronic noise. The second half was fixed in formalin, embedded in paraffin, cut at a 4-&#x000b5;m thickness in the same plane as the MRI acquisition, and then stained using Masson&#x02019;s Trichrome and Perls. The minimum processing time for pathology samples was around 48&#x02009;h. All histology slides were digitally scanned using the Ventana DP 200 slide scanner (Roche, Basel, Switzerland). The low magnification used ranged between 1&#x000d7; and 2&#x000d7;, depending on the sample, and the scale bar was indicated for each microphotograph.<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic diagram of the overall workflow of the study</p></caption><graphic xlink:href="41747_2025_589_Fig1_HTML" id="d33e554"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Sequence parameters for the rapid imaging with refocused echoes (RARE) T2-weighted sequence</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Repetition time (ms)</th><th>Echo time (ms)</th><th>Number of excitations</th><th>RARE factor</th><th>Matrix</th><th>Slice thickness (&#x000b5;m)</th><th>Field-of-view (mm)</th><th>Spatial resolution (&#x000b5;m)</th><th>Acquisition time (min)</th></tr></thead><tbody><tr><td>3,000</td><td>30</td><td>25</td><td>2</td><td>266 &#x000d7; 200 &#x000d7; 42</td><td>200</td><td>20 &#x000d7; 15 &#x000d7; 6</td><td>75 &#x000d7; 75 &#x000d7; 200</td><td>240</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Assessment of MRI and pathology images</title><p id="Par20">Three subspecialty-trained abdominal radiologists (B.G., V.V., and A.V., with 27, 35, and 7 years of experience, respectively) and three subspecialty-trained abdominal pathologists (A.F., V.P., and A.B. with 5, 30, and 10 years of experience) assessed both MRI and pathology images, independently and blinded to medical records. The readings of MRI and pathology images were conducted in two separate sessions, over a month apart.</p><sec id="Sec5"><title>Pathology images</title><p id="Par21">In the first session, the three pathologists independently staged fibrosis on digital histological slides according to the METAVIR score using the software QuPath&#x000ae; [<xref ref-type="bibr" rid="CR16">16</xref>]. The consensus fibrosis stage for pathology was based on the agreement of at least two of the three pathologists.</p></sec><sec id="Sec6"><title>MRI</title><p id="Par22">The second session consisted of the reading of MRI images using 3D Slicer [<xref ref-type="bibr" rid="CR17">17</xref>], the cases being presented in a different random order, by all three radiologists and three pathologists, given that this new field of application is halfway between the two specialities. First, all readers (radiologists and pathologists) received training on the METAVIR classification of fibrosis and the semiology of the fibrosis on high-field MRI (MRI-METAVIR score as described below), using two previously published cases [<xref ref-type="bibr" rid="CR8">8</xref>] and schematic illustrations of high-field MRI for each stage (F0 to F4, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Then, all reviewers were asked to review the MRI images (6 images per patient) and stage fibrosis, according to the MRI-METAVIR score. The consensus fibrosis stage for MRI was based distinctively on the agreement of at least 2 two of the three radiologists and on the agreement of at least two of the three radiologists. To create the MRI-METAVIR score, one subspecialty-trained abdominal radiologist who did not participate in the reading (J.D., with 3 years of experience) reviewed all MRI images and analysed the MRI features of fibrosis in correlation with their corresponding histological section. The MRI-METAVIR score has been developed in analogy with the histological staging criteria, based on the presence and distribution of fibrosis [<xref ref-type="bibr" rid="CR8">8</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic illustrations of the MRI-METAVIR score with high-resolution liver magnetic resonance imaging and histopathology correlation (Masson&#x02019;s Trichrome) in a normal liver (<bold>a</bold>, <bold>d</bold>), F3 liver T2 (<bold>b</bold>, <bold>e</bold>), and F4 (cirrhosis) liver (<bold>c</bold>, <bold>f</bold>). On <bold>a</bold> and <bold>d</bold>, the liver architecture is homogeneous with hyperintense punctate portal spaces (arrow) and centrilobular veins (arrowhead). On <bold>b</bold> and <bold>e</bold>, the liver architecture is distorted by numerous T2 hyperintense fibrotic septa (arrowhead) with lobules of different size, shape, and signal (arrow). On <bold>c</bold> and <bold>f</bold>, there are regenerative cirrhotic nodules (arrow) separated by fibrotic septa (arrowhead)</p></caption><graphic xlink:href="41747_2025_589_Fig2_HTML" id="d33e682"/></fig></p></sec></sec><sec id="Sec7"><title>Reference standard</title><p id="Par23">The reference standard was the consensus fibrosis METAVIR stage based on the agreement of at least two of the three pathologists using the pathology images only.</p></sec><sec id="Sec8"><title>Endpoint</title><p id="Par24">The endpoint of the study was the performance of 7-T MRI to diagnose advanced fibrosis (stage F3 or F4) in fresh <italic>ex vivo</italic> liver tissue using the newly developed MRI-METAVIR score.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par25">Performance metrics of MRI were computed for sensitivity, specificity, accuracy, positive and negative predictive values, area under the receiver operating characteristic curve, and c-index. Paired ordinal non-normally distributed data were compared with the Wilcoxon signed-rank test. The concordance between the pathologic gold standard and the MRI consensus was calculated using weighted &#x003ba; (linear weights). The inter-reader agreement was calculated using Fleiss &#x003ba; [<xref ref-type="bibr" rid="CR18">18</xref>]. The agreement was interpreted according to &#x003ba; values as follows: &#x0003c; 0.00 (poor); 0.00&#x02013;0.20 (slight); 0.21&#x02013;0.40 (fair); 0.41&#x02013;0.60 (moderate); 0.61&#x02013;0.80 (substantial); 0.81&#x02013;1.00 (almost perfect) [<xref ref-type="bibr" rid="CR19">19</xref>]. All statistical analysis was performed using MedCalc Statistical Software version 23.0.5 (MedCalc Software bv, Ostend, Belgium; <ext-link ext-link-type="uri" xlink:href="https://www.medcalc.org">https://www.medcalc.org</ext-link>) and SPSS Statistics version 29 (IBM, IBM Corporation, New York, USA).</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Population</title><p id="Par26">A total of 20 consecutive patients scheduled for liver surgery were included in the study. There was no adverse event or complication during the specimen collection or MRI procedure. Three patients were excluded due to poor specimen quality, not allowing MRI or pathology examination (<italic>n</italic>&#x02009;=&#x02009;1) and cancellation of the surgery (<italic>n</italic>&#x02009;=&#x02009;2). In addition, two of the 20 included patients, previously published [<xref ref-type="bibr" rid="CR2">2</xref>], were used for reader training and not included in the final dataset. The final dataset consisted of 15 patients, 12 men and 3 women, with a median age of 68 years, interquartile range 60&#x02013;73, who underwent liver surgery for primary liver lesions (<italic>n</italic>&#x02009;=&#x02009;10) or colorectal cancer liver metastases (<italic>n</italic>&#x02009;=&#x02009;5). Chronic liver disease of several aetiologies was present in 10 of 15 patients (67%) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographics, clinical characteristics, surgical indications, and results of consensus review of pathology slides and 7-T magnetic resonance imaging fibrosis staging</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age (years)</th><th>Sex</th><th>Chronic liver disease</th><th>Surgical indication</th><th>Pathological fibrosis stage</th><th>MRI fibrosis stage</th></tr></thead><tbody><tr><td>59</td><td>M</td><td>Hepatitis B and C viruses</td><td>Hepatocellular carcinoma</td><td>F2</td><td>Training</td></tr><tr><td>49</td><td>F</td><td>None</td><td>Metastases</td><td>F0</td><td>Training</td></tr><tr><td>73</td><td>M</td><td>MASLD</td><td>Hepatocellular carcinoma</td><td>F1</td><td>F0</td></tr><tr><td>57</td><td>M</td><td>Indeterminate aetiology</td><td>Metastases</td><td>F3</td><td>F2</td></tr><tr><td>73</td><td>M</td><td>None</td><td>Metastases</td><td>F0</td><td>F0</td></tr><tr><td>64</td><td>M</td><td>MetALD (MASLD and increased alcohol intake)</td><td>Hepatocellular carcinoma</td><td>F3</td><td>F3</td></tr><tr><td>58</td><td>M</td><td>None</td><td>Biliary cystadenoma</td><td>F1</td><td>F1</td></tr><tr><td>65</td><td>M</td><td>Alcohol associated liver disease</td><td>Hepatocellular carcinoma</td><td>F4</td><td>F4</td></tr><tr><td>73</td><td>M</td><td>MetALD (MASLD and increased alcohol intake)</td><td>Hepatocellular carcinoma</td><td>F1</td><td>F1</td></tr><tr><td>72</td><td>F</td><td>Alcohol associated liver disease</td><td>Hepatocellular carcinoma</td><td>F3</td><td>F4</td></tr><tr><td>71</td><td>M</td><td>None</td><td>Metastases</td><td>F1</td><td>F0</td></tr><tr><td>62</td><td>M</td><td>Alcohol associated liver disease</td><td>Hepatocellular carcinoma</td><td>F4</td><td>F4</td></tr><tr><td>56</td><td>F</td><td>None</td><td>Metastases</td><td>F0</td><td>F0</td></tr><tr><td>68</td><td>M</td><td>Indeterminate aetiology</td><td>Hepatocellular carcinoma</td><td>F3</td><td>F3</td></tr><tr><td>60</td><td>F</td><td>None</td><td>Metastases</td><td>F1</td><td>F1</td></tr><tr><td>68</td><td>M</td><td>Alcohol associated liver disease</td><td>Hepatocellular carcinoma</td><td>F3</td><td>F4</td></tr><tr><td>80</td><td>M</td><td>MASLD</td><td>Hepatocellular carcinoma</td><td>F4</td><td>F4</td></tr></tbody></table><table-wrap-foot><p><italic>F</italic> Female, <italic>M</italic> Male, <italic>MASLD</italic> Metabolic dysfunction-associated steatotic liver disease</p></table-wrap-foot></table-wrap></p><p id="Par27">The pathologists&#x02019; consensus results for fibrosis staging on Masson&#x02019;s Trichrome-stained slides, which served as a reference standard, were as follows: 2 of 15 patients (13%) had a METAVIR stage of F0, 5 (33%) of F1, 5/15 (33%) of F3, and 3/15 (20%) of F4 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In all cases, no consensus review was necessary, and the agreement between the pathologists regarding the review of histopathology images was very good (&#x003ba;&#x02009;=&#x02009;0.77, 95% confidence interval (CI) 0.61&#x02013;0.93).</p></sec><sec id="Sec12"><title>Accuracy of MRI</title><p id="Par28">The diagnostic performances of MRI for a histopathology-like diagnosis of the absence (F0) or very early (F1) fibrosis, and the presence of advanced fibrosis (F3 or F4), were excellent for both radiologists and pathologists (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Radiologists achieved an 88% sensitivity (95% CI 47&#x02013;100%), 100% specificity (59&#x02013;100%), 100% positive predictive value (59&#x02013;100%), 88% negative predictive value (95% CI 53&#x02013;98%), 93% accuracy (95% CI 68&#x02013;100%), 0.94 AUC (95% CI 0.69&#x02013;1.0%) and 0.94 Harrell&#x02019;s c-index (95% CI 0.86&#x02013;1.0%). Pathologists achieved 88% sensitivity (95% CI 47&#x02013;100%), 86% specificity (95% CI 42&#x02013;100%), 88% positive predictive value (95% CI 53&#x02013;98%), 86% negative predictive value (95% CI 48&#x02013;98%), 87% accuracy (95% CI 60&#x02013;98%), 0.87 AUC (95% CI 0.60&#x02013;0.98%), and 0.87 Harrell&#x02019;s c-index (95% CI 0.74&#x02013;0.99). There were no statistically significant differences between MRI stages and pathologic gold standard stages (<italic>p</italic>&#x02009;=&#x02009;0.655 for radiologists and <italic>p</italic>&#x02009;=&#x02009;1.000 for pathologists). MRI correctly classified 7 of 8 patients with advanced fibrosis on pathology (1 patient was staged F2 on MRI but was F3 on histopathology). Conversely, MRI correctly excluded fibrosis (<italic>i.e</italic>., F0 or F1 stages) in 7 of 7 compared to histopathology. The concordance of MRI analysis with histopathology was excellent for radiologists (&#x003ba;&#x02009;=&#x02009;0.81; 95% CI 0.67&#x02013;0.95) and moderate for pathologists (&#x003ba;&#x02009;=&#x02009;0.50; 95% CI 0.26&#x02013;0.73) for all fibrosis stages. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows a discordant case between MRI assessment and histopathologic gold standard.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Diagnostic performances and concordance (weighted &#x003ba;) of MRI with pathologic reference standard to identify and stage hepatic fibrosis and inter-reader agreement</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">Inter-reader agreement</th><th colspan="4">Agreement with pathologic reference standard</th></tr><tr><th>Ratio</th><th>Accuracy</th><th>Harrell&#x02019;s c-index</th><th>Weighted &#x003ba;</th></tr></thead><tbody><tr><td colspan="6">Radiologists</td></tr><tr><td>&#x02003;No or very early fibrosis (F0-F1)</td><td rowspan="2">&#x003ba;&#x02009;=&#x02009;0.32 [0.29&#x02013;0.61]</td><td>7/7</td><td rowspan="2">93% [68&#x02013;100%]</td><td rowspan="2">0.94 [0.86&#x02013;1.00]</td><td rowspan="2">&#x003ba;&#x02009;=&#x02009;0.87 [0.62&#x02013;1.0]</td></tr><tr><td>&#x02003;Advanced fibrosis (F3-F4)</td><td>7/8</td></tr><tr><td colspan="6">Pathologists</td></tr><tr><td>&#x02003;No or very early fibrosis (F0-F1)</td><td rowspan="2">&#x003ba;&#x02009;=&#x02009;0.82 [0.53&#x02013;1.00]</td><td>6/7</td><td rowspan="2">87% [60&#x02013;98%]</td><td rowspan="2">0.87 [0.74&#x02013;0.99]</td><td rowspan="2">&#x003ba;&#x02009;=&#x02009;0.73 [0.39&#x02013;1.0]</td></tr><tr><td>&#x02003;Advanced fibrosis (F3-F4)</td><td>7/8</td></tr></tbody></table><table-wrap-foot><p>Inter-reader agreement was calculated using Fleiss &#x003ba;. 95% confidence intervals in squared brackets</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Staging discrepancy between 7-T MRI and histological reference standard. 7-T MRI (<bold>a</bold>) was staged F2 because of early changes in the lobular architecture and rare fibrotic septa (arrow) seen between the portal spaces, while histology (<bold>b</bold>) was staged F3 because of numerous fibrotic septa (arrow). <bold>c</bold> and <bold>d</bold> illustrate another example where 7-T MRI (<bold>c</bold>) was staged F3 due to numerous fibrotic septa (arrow) while histology (<bold>d</bold>) was staged F4 due to regenerative nodules (star)</p></caption><graphic xlink:href="41747_2025_589_Fig3_HTML" id="d33e1120"/></fig></p><p id="Par29">The inter-reader agreement between the six readers was moderate (&#x003ba;&#x02009;=&#x02009;0.42; 95% CI 0.29&#x02013;0.55), fair between the three radiologists (&#x003ba;&#x02009;=&#x02009;0.32; 95% CI 0.29&#x02013;0.61) but almost perfect between the three pathologists (&#x003ba;&#x02009;=&#x02009;0.82; 95% CI 0.53&#x02013;1.00).</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p id="Par30">High-field 7-T MRI demonstrated excellent performance in accurately staging liver fibrosis compared to histopathology, highlighting its potential as an innovative surrogate or complementary tool for low-magnification histology. Indeed, this study showed that the 7-T MRI can provide sufficient contrast between tissues to enable histopathology-like examination without the need for staining [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In addition, MRI has the undeniable advantage over histology of being able to acquire images in a relatively short time with immediate image interpretation, as with any routine MRI. The specimen, which remains intact, can still be processed for pathologic examination afterward [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par31">Reaching very high in-plane spatial resolution (~&#x02009;75 &#x000d7; 75 &#x000b5;m<sup>2</sup>), close to that of low-magnification histology [<xref ref-type="bibr" rid="CR20">20</xref>], MRI provided a completely new insight into the imaging of the liver architecture, which would not have been visible with the in-plane spatial resolution of a clinical standard MRI (~&#x02009;1 mm<sup>2</sup>) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Fibrotic changes to the liver parenchyma observed on Masson&#x02019;s trichrome-stained histology slides were readily depictable on high-field MRI, appearing as T2-weighted hyperintense septa [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] together with fibrosis-related micro-architectural distortions at early stages [<xref ref-type="bibr" rid="CR23">23</xref>]. While MRI has indeed a lower spatial resolution compared to histology, it provides a comprehensive assessment of liver micro-architecture, enabling the evaluation of fibrosis-related structural changes, beyond the limitations of two-dimensional histological slices. Unlike histology, which relies on two-dimensional sectioning, MRI allows for the evaluation of larger and intact tissue volumes, minimising sampling bias and preserving the native tissue structure, without the need for fixation or staining [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Although histology remains the standard of care, it is subject to tissue-processing artifacts and sampling bias, whereas MRI provides a more comprehensive imaging.</p><p id="Par32">Regarding the choice of MRI sequence, T2-weighted RARE provided an optimal balance between high in-plane spatial resolution (75 &#x000d7; 75 &#x000b5;m<sup>2</sup>) and contrast resolution, allowing detailed visualisation of liver micro-architecture and fibrotic tracts. Thus, the spatial resolution was optimised by adjusting acquisition parameters to maximise signal-to-noise ratio while maintaining a reasonable scanning time to prevent sample degradation.</p><p id="Par33">While consensus MRI results were excellent, the inter-reader agreement between radiologists was poorer than that of pathologists. This was expected as the three radiologists had no experience with these images prior to this reading. Their only training consisted of a session based on two previously published pathological images and schematic representations, which were not representative of all stages of fibrosis. This was done to keep as many cases as possible in the final reading set. Of note, when the METAVIR score was first used by pathologists, its interobserver reproducibility was also poor [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par34">The main limitation of this proof-of-concept study is the limited number of patients without any patients with F2 stage fibrosis. However, Dana et al [<xref ref-type="bibr" rid="CR8">8</xref>] reported a case of F0 <italic>versus</italic> F2 accurate staging on high-field MRI, which also highlights the promising potential of the MRI-METAVIR score. Although these findings should be confirmed in a more extensive cohort, the number of expert reviewers for MRI and histology images strengthens the validity of the MRI-METAVIR score. On the other hand, the limited number of patients did not represent the full spectrum of liver conditions. Also, in case of iron overload in the liver, there is shortening of T2/T2* relaxation times, which is even worsened at 7&#x02009;T, which can result in decreased signal-to-noise ratio [<xref ref-type="bibr" rid="CR25">25</xref>]. Similarly, a fixed echo time could also influence contrast in cases of hepatic steatosis, and future studies are required to address this more specifically. In addition, although the samples were placed in Fluorinert&#x02122; Electronic Liquid FC40, a nonconductive, thermally and chemically stable fluid without <sup>1</sup>H signal, the limited number of patients did not allow us to investigate the impact of the specific absorption rates and excessive heat on the samples. Another limitation is the very low number of cases (<italic>n</italic>&#x02009;=&#x02009;2) in the training set, related to sample availability. Despite this limitation, the diagnostic performance of radiologists to accurately stage fibrosis did not appear to have been significantly impacted (sensitivity 88%, specificity 100%).</p><p id="Par35">This study paves the way for further applications of this technique to organs other than the liver. By offering direct, pathology-like access to the micro-architecture of <italic>ex vivo</italic> tissue samples, high-field MRI opens up a range of new applications. This noninvasive technique broadens the scope of tissue imaging possibilities of liver, brain, brainstem, lymph nodes, or atherosclerotic plaque [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. In surgical oncology, this technique would be particularly useful for a simplified, noninvasive, real-time analysis of surgical specimens. For instance, several attempts to assess the <italic>ex vivo</italic> lymph node metastatic status in breast cancer yielded promising results despite long acquisition time [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Similarly, oncological surgeries requiring extemporaneous analysis of tissues could also benefit from this nondestructive analysis to assess tumour margins (<italic>e.g</italic>., partial nephrectomy, bronchial resection margins in lung cancer surgery) where the margins of a tumour could be rapidly assessed in their entirety as a three-dimensional volume without specific preparation (<italic>i.e</italic>., including cutting) the specimen. Additionally, volumetric images of the entire specimen could help reduce sampling errors on macroscopic evaluation of the specimens, by providing more relevant mappings than macroscopic &#x0201c;naked eye&#x0201d; analysis, to select areas to be sectioned for further histological analysis. However, the broader use of this technique as a surrogate for extemporaneous analysis has been limited by several factors, including prolonged acquisition times and the high cost and limited availability of the equipment, particularly in oncologic surgery, where perioperative decisions require rapid turnaround times. While current MRI acquisition times remain impractical for intraoperative use and/or extemporaneous examination, ongoing technological advancements, such as improved MRI coils or accelerated acquisition techniques, will hopefully significantly reduce scanning times while preserving sufficient spatial resolution and signal-to-noise ratio.</p><p id="Par36">Furthermore, this method could also improve radiologists&#x02019; understanding of clinical MRI, as MRI features of diseases have often been established on an empirical basis, while the underlying pathological mechanisms inducing signal changes are not always well understood. New information, such as tissue hydration or fibrosis, may become accessible and quantifiable, in addition to the possibility of examining the entire volume of a sample without destruction [<xref ref-type="bibr" rid="CR29">29</xref>]. In chronic liver disease, a better understanding of the normal and pathological micro-architecture of the liver parenchyma is fully in line with the current drive to develop noninvasive imaging biomarkers aiming to go beyond histopathology, aiming at replacing liver biopsies [<xref ref-type="bibr" rid="CR30">30</xref>] but remains mostly limited to MRI elastography in fibrosis [<xref ref-type="bibr" rid="CR31">31</xref>]. Thus, by providing unparalleled images of the liver micro-architecture, high-field MRI bridges the gap between clinical MRI and histopathology, providing a better understanding of the anatomical basis of clinical <italic>in vivo</italic> MRI. However, for that purpose and without being able to use a cryoprobe with clinical MRI, major technological developments are required to translate this technique, focusing on reducing breathing and motion artifacts and improving coil design. Additionally, our MRI-based results also outline potential novel research directions, such as the use of machine learning for automated fibrosis detection.</p><p id="Par37">To demonstrate that MRI could be disruptively used to provide a histopathology-like examination, we needed a model allowing qualitative and quantitative analysis. Liver fibrosis appeared as an appropriate model because of the existence of widely validated histological classifications of liver fibrosis, with low subjectivity, such as the METAVIR score on Masson&#x02019;s trichrome-stained sections [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. The METAVIR score, validated in chronic viral hepatitis, was chosen as a uniform scoring system for all cases, regardless of the aetiology of liver disease. This represents a limitation as specific features such as perisinusoidal or perivenular fibrosis in the context of steatohepatitis were not considered. Furthermore, no patients with chronic viral hepatitis were included. Nevertheless, it enabled a fully blinded review of the cases without bias from known chronic liver disease. Further research with a larger patient cohort and various aetiologies of liver disease is required to refine our understanding of 7-T MRI liver semiology and evaluate different liver fibrosis stages, as the impact of potential confounding factors may have been overlooked in this preliminary study.</p><p id="Par38">High-field 7-T MRI provides an assessment similar to low-magnification histology (1&#x000d7;&#x02013;2&#x000d7;). Beyond fibrosis staging of liver tissue, MRI enables a cross-sectional volumetric exploration of the entire specimen, without cutting or destroying the sample. With short-time image acquisition and immediate image reading, high-field MRI could become a new modality for extemporaneous tissue analysis, especially in oncologic surgery. On the other hand, future research developments should focus on bridging the gap with <italic>in vivo</italic> MRI to impact clinical practice and provide true noninvasive microscopic histologic examination.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p id="Par11">Confidence interval</p></def></def-item><def-item><term>MRI</term><def><p id="Par12">Magnetic resonance imaging</p></def></def-item><def-item><term>RARE</term><def><p id="Par13">Rapid imaging with refocused echoes</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We did not use LLMs or other generative AI tools to write this article.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>A&#x000ef;na Venkatasamy and Benoit Gallix jointly conceived the study. Patrick Pessaux and Thomas F Baumert provided ethics committee approval and liver samples. Chrystelle Po performed all imaging experiments with the support of A&#x000ef;na Venkatasamy&#x000a0;and&#x000a0;J&#x000e9;r&#x000e9;my Dana. J&#x000e9;r&#x000e9;my Dana curated and analysed the data. Antonin Fattori supervised the preparation of the sample and pathology staining. J&#x000e9;r&#x000e9;my Dana reviewed all images and organised the reading sessions. A&#x000ef;na Venkatasamy, Benoit Gallix, Val&#x000e9;rie Vilgrain, Antonin Fattori, Aur&#x000e9;lie Beaufr&#x000e8;re and Val&#x000e9;rie Paradis read all MR and pathology images. J&#x000e9;r&#x000e9;my Dana, A&#x000ef;na Venkatasamy, and Beno&#x000ee;t Gallix wrote the manuscript. All authors reviewed, edited, and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>FONDATION ARC, Grant/Award Number: TheraHCC2.0 IHU201901299 (TFB and BG). TFB was supported by the European Union (ERC-AdG-2020-FIBCAN #101021417), the French state funds managed within the &#x0201c;Plan Investissements d&#x02019;Avenir&#x0201d; and by the ANR (references ANR-10-IAHU-02 and ANR-10-LABX-0028), along with French state funds managed by the ANR within the France 2030 program (reference ANR-21-RHUS-0001). This work of the Interdisciplinary Thematic Institute IMCBio, as part of the ITI 2021-2028 program of the University of Strasbourg, CNRS and Inserm, was supported by IdEx Unistra (ANR-10-IDEX-0002), and by SFRI-STRAT&#x02019;US project (ANR 20-SFRI-0012) and EUR IMCBio (ANR-17-EURE-0023) under the framework of the French Investments for the Future Program as well as IUF.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data are available on demand at IHU Strasbourg (corresponding author AV).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par39">This prospective project was approved by the Research Ethics Board (Protocol RIPH2, LivMod N&#x000b0;IDRCB 2019-A00738-49 ClinicalTrial NCT04690972) and followed ethical principles of the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par40">All patients provided written informed consent.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par41">AV is a member of the Scientific Editorial Board of <italic>European Radiology Experimental</italic> (section: Abdomen/gastrointestinal) and, as such, did not participate in the selection or review processes for this article. The remaining authors declare no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Volmar</surname><given-names>KE</given-names></name><name><surname>Idowu</surname><given-names>MO</given-names></name><name><surname>Souers</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Turnaround time for large or complex specimens in surgical pathology: a College of American Pathologists Q-Probes study of 56 institutions</article-title><source>Arch Pathol Lab Med</source><year>2015</year><volume>139</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0671-CP</pub-id><pub-id pub-id-type="pmid">25611100</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Volmar KE, Idowu MO, Souers RJ et al (2015) Turnaround time for large or complex specimens in surgical pathology: a College of American Pathologists Q-Probes study of 56 institutions. Arch Pathol Lab Med 139:171&#x02013;177. 10.5858/arpa.2013-0671-CP<pub-id pub-id-type="pmid">25611100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Novis</surname><given-names>DA</given-names></name><name><surname>Zarbo</surname><given-names>RJ</given-names></name></person-group><article-title>Interinstitutional comparison of frozen section turnaround time. A College of American Pathologists Q-Probes study of 32868 frozen sections in 700 hospitals</article-title><source>Arch Pathol Lab Med</source><year>1997</year><volume>121</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0671-cp</pub-id><pub-id pub-id-type="pmid">9199619</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Novis DA, Zarbo RJ (1997) Interinstitutional comparison of frozen section turnaround time. A College of American Pathologists Q-Probes study of 32868 frozen sections in 700 hospitals. Arch Pathol Lab Med 121:559&#x02013;567. 10.5858/arpa.2013-0671-cp<pub-id pub-id-type="pmid">9199619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Berho</surname><given-names>M</given-names></name><name><surname>Jeffers</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection</article-title><source>Am J Gastroenterol</source><year>2002</year><volume>97</volume><fpage>2614</fpage><lpage>2618</lpage><pub-id pub-id-type="doi">10.1002/hep.21346</pub-id><pub-id pub-id-type="pmid">12385448</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Regev A, Berho M, Jeffers LJ et al (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97:2614&#x02013;2618. 10.1002/hep.21346<pub-id pub-id-type="pmid">12385448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Merriman</surname><given-names>RB</given-names></name><name><surname>Ferrell</surname><given-names>LD</given-names></name><name><surname>Patti</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><fpage>874</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1002/hep.21346</pub-id><pub-id pub-id-type="pmid">17006934</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Merriman RB, Ferrell LD, Patti MG et al (2006) Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44:874&#x02013;480. 10.1002/hep.21346<pub-id pub-id-type="pmid">17006934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Potretzke</surname><given-names>TA</given-names></name><name><surname>Saling</surname><given-names>LJ</given-names></name><name><surname>Middleton</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Bleeding complications after percutaneous liver biopsy: do subcapsular lesions pose a higher risk?</article-title><source>AJR Am J Roentgenol</source><year>2018</year><volume>211</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.2214/ajr.17.18726</pub-id><pub-id pub-id-type="pmid">29708780</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Potretzke TA, Saling LJ, Middleton WD et al (2018) Bleeding complications after percutaneous liver biopsy: do subcapsular lesions pose a higher risk? AJR Am J Roentgenol 211:204&#x02013;210. 10.2214/ajr.17.18726<pub-id pub-id-type="pmid">29708780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Baltes</surname><given-names>C</given-names></name><name><surname>Radzwill</surname><given-names>N</given-names></name><name><surname>Bosshard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Micro MRI of the mouse brain using a novel 400&#x02009;MHz cryogenic quadrature RF probe</article-title><source>NMR Biomed</source><year>2009</year><volume>22</volume><fpage>834</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1002/nbm.1396</pub-id><pub-id pub-id-type="pmid">19536757</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Baltes C, Radzwill N, Bosshard S et al (2009) Micro MRI of the mouse brain using a novel 400&#x02009;MHz cryogenic quadrature RF probe. NMR Biomed 22:834&#x02013;442. 10.1002/nbm.1396<pub-id pub-id-type="pmid">19536757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Dashevsky</surname><given-names>BZ</given-names></name><name><surname>D&#x02019;Alfonso</surname><given-names>T</given-names></name><name><surname>Sutton</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>The potential of high resolution magnetic resonance microscopy in the pathologic analysis of resected breast and lymph tissue</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>17435</fpage><pub-id pub-id-type="doi">10.1038/srep17435</pub-id><pub-id pub-id-type="pmid">26639673</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dashevsky BZ, D&#x02019;Alfonso T, Sutton EJ et al (2015) The potential of high resolution magnetic resonance microscopy in the pathologic analysis of resected breast and lymph tissue. Sci Rep 5:17435. 10.1038/srep17435<pub-id pub-id-type="pmid">26639673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dana</surname><given-names>J</given-names></name><name><surname>Venkatasamy</surname><given-names>A</given-names></name></person-group><article-title>High-resolution (7-T) liver MRI for pathologic examination</article-title><source>Radiology</source><year>2022</year><volume>306</volume><fpage>74</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1148/radiol.220410</pub-id><pub-id pub-id-type="pmid">36066363</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dana J, Venkatasamy A (2022) High-resolution (7-T) liver MRI for pathologic examination. Radiology 306:74&#x02013;75. 10.1148/radiol.220410<pub-id pub-id-type="pmid">36066363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Korteweg</surname><given-names>MA</given-names></name><name><surname>Zwanenburg</surname><given-names>JJM</given-names></name><name><surname>Hoogduin</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Dissected sentinel lymph nodes of breast cancer patients: characterization with high-spatial-resolution 7-T MR imaging</article-title><source>Radiology</source><year>2011</year><volume>261</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1148/radiol.11103535</pub-id><pub-id pub-id-type="pmid">21673230</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Korteweg MA, Zwanenburg JJM, Hoogduin JM et al (2011) Dissected sentinel lymph nodes of breast cancer patients: characterization with high-spatial-resolution 7-T MR imaging. Radiology 261:127&#x02013;135. 10.1148/radiol.11103535<pub-id pub-id-type="pmid">21673230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Van Natta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Design and validation of a histological scoring system for nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2005</year><volume>41</volume><fpage>1313</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1002/hep.20701</pub-id><pub-id pub-id-type="pmid">15915461</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313&#x02013;1321. 10.1002/hep.20701<pub-id pub-id-type="pmid">15915461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Desmet</surname><given-names>VJ</given-names></name><name><surname>Gerber</surname><given-names>M</given-names></name><name><surname>Hoofnagle</surname><given-names>JH</given-names></name><name><surname>Manns</surname><given-names>M</given-names></name><name><surname>Scheuer</surname><given-names>PJ</given-names></name></person-group><article-title>Classification of chronic hepatitis: diagnosis, grading and staging</article-title><source>Hepatology</source><year>1994</year><volume>19</volume><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1002/hep.1840190629</pub-id><pub-id pub-id-type="pmid">8188183</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513&#x02013;1520<pub-id pub-id-type="pmid">8188183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Poynard</surname><given-names>T</given-names></name></person-group><article-title>An algorithm for the grading of activity in chronic hepatitis C</article-title><source>Hepatology</source><year>1996</year><volume>24</volume><fpage>289</fpage><lpage>2893</lpage><pub-id pub-id-type="doi">10.1002/hep.510240201</pub-id><pub-id pub-id-type="pmid">8690394</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24:289&#x02013;2893. 10.1002/hep.510240201<pub-id pub-id-type="pmid">8690394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>AM</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Tapper</surname><given-names>EB</given-names></name></person-group><article-title>Contemporary epidemiology of chronic liver disease and cirrhosis</article-title><source>Clin Gastroenterol Hepatol</source><year>2020</year><volume>18</volume><fpage>2650</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2019.07.060</pub-id><pub-id pub-id-type="pmid">31401364</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18:2650&#x02013;2666. 10.1016/j.cgh.2019.07.060<pub-id pub-id-type="pmid">31401364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>Found in translation&#x02014;fibrosis in metabolic dysfunction&#x02013;associated steatohepatitis (MASH)</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><fpage>eadi0759</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adi0759</pub-id><pub-id pub-id-type="pmid">37792957</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wang S, Friedman SL (2023) Found in translation&#x02014;fibrosis in metabolic dysfunction&#x02013;associated steatohepatitis (MASH). Sci Transl Med 15:eadi0759. 10.1126/scitranslmed.adi0759<pub-id pub-id-type="pmid">37792957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Dana</surname><given-names>J</given-names></name><name><surname>Venkatasamy</surname><given-names>A</given-names></name><name><surname>Saviano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease</article-title><source>Hepatology Int</source><year>2022</year><volume>16</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s12072-022-10303-0</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Dana J, Venkatasamy A, Saviano A et al (2022) Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatology Int 16:509&#x02013;522. 10.1007/s12072-022-10303-0</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><name><surname>Loughrey</surname><given-names>MB</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>JA</given-names></name><etal/></person-group><article-title>QuPath: open source software for digital pathology image analysis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>16878</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17204-5</pub-id><pub-id pub-id-type="pmid">29203879</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Bankhead P, Loughrey MB, Fern&#x000e1;ndez JA et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. 10.1038/s41598-017-17204-5<pub-id pub-id-type="pmid">29203879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Kikinis R, Pieper SD, Vosburgh KG (2013) 3D Slicer: a platform for subject-specific image analysis, visualization, and clinical support. In: Jolesz FA (ed) Intraoperative imaging and image-guided therapy. Springer, New York. <ext-link ext-link-type="uri" xlink:href="https://link.springer.com/chapter/10.1007/978-1-4614-7657-3_19">https://link.springer.com/chapter/10.1007/978-1-4614-7657-3_19</ext-link></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Fleiss JL, Levin B, Paik MC (2003) The measurement of interrater agreement. In: Statistical methods for rates and proportions, 3rd edn. Wiley, New York. 10.1002/0471445428</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>JR</given-names></name><name><surname>Koch</surname><given-names>GG</given-names></name></person-group><article-title>The measurement of observer agreement for categorical data</article-title><source>Biometrics</source><year>1977</year><volume>33</volume><fpage>159</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.2307/2529310</pub-id><pub-id pub-id-type="pmid">843571</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159&#x02013;174<pub-id pub-id-type="pmid">843571</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>DeRose</surname><given-names>JA</given-names></name><name><surname>Doppler</surname><given-names>M</given-names></name></person-group><article-title>Guidelines for understanding magnification in the modern digital microscope era</article-title><source>Microscopy Today</source><year>2018</year><volume>26</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1017/S1551929518000688</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">DeRose JA, Doppler M (2018) Guidelines for understanding magnification in the modern digital microscope era. Microscopy Today 26:20&#x02013;33. 10.1017/S1551929518000688</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Faria</surname><given-names>SC</given-names></name><name><surname>Ganesan</surname><given-names>K</given-names></name><name><surname>Mwangi</surname><given-names>I</given-names></name><etal/></person-group><article-title>MR imaging of liver fibrosis: current state of the art</article-title><source>Radiographics</source><year>2009</year><volume>29</volume><fpage>1615</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1148/rg.296095512</pub-id><pub-id pub-id-type="pmid">19959511</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Faria SC, Ganesan K, Mwangi I et al (2009) MR imaging of liver fibrosis: current state of the art. Radiographics 29:1615&#x02013;1635. 10.1148/rg.296095512<pub-id pub-id-type="pmid">19959511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Serai</surname><given-names>SD</given-names></name><name><surname>Trout</surname><given-names>AT</given-names></name><name><surname>Miethke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis</article-title><source>Pediatr Radiol</source><year>2018</year><volume>48</volume><fpage>1256</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1007/s00247-018-4083-2</pub-id><pub-id pub-id-type="pmid">30078038</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Serai SD, Trout AT, Miethke A et al (2018) Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis. Pediatr Radiol 48:1256&#x02013;1272. 10.1007/s00247-018-4083-2<pub-id pub-id-type="pmid">30078038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Minamikawa</surname><given-names>T</given-names></name><name><surname>Hase</surname><given-names>E</given-names></name><name><surname>Ichimura-Shimizu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of ultra-early-stage liver fibrosis in human non-alcoholic fatty liver disease by second-harmonic generation microscopy</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>3357</fpage><pub-id pub-id-type="doi">10.3390/ijms23063357</pub-id><pub-id pub-id-type="pmid">35328778</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Minamikawa T, Hase E, Ichimura-Shimizu M et al (2022) Assessment of ultra-early-stage liver fibrosis in human non-alcoholic fatty liver disease by second-harmonic generation microscopy. Int J Mol Sci 23:3357. 10.3390/ijms23063357<pub-id pub-id-type="pmid">35328778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Rousselet</surname><given-names>MC</given-names></name><name><surname>Michalak</surname><given-names>S</given-names></name><name><surname>Dupr&#x000e9;</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sources of variability in histological scoring of chronic viral hepatitis</article-title><source>Hepatology</source><year>2005</year><volume>41</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1002/hep.20535</pub-id><pub-id pub-id-type="pmid">15660389</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rousselet MC, Michalak S, Dupr&#x000e9; F et al (2005) Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41:257&#x02013;264. 10.1002/hep.20535<pub-id pub-id-type="pmid">15660389</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ladd</surname><given-names>ME</given-names></name><name><surname>Bachert</surname><given-names>P</given-names></name><name><surname>Meyerspeer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pros and cons of ultra-high-field MRI/MRS for human application</article-title><source>Prog Nucl Magn Reson Spectrosc</source><year>2018</year><volume>109</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.pnmrs.2018.06.001</pub-id><pub-id pub-id-type="pmid">30527132</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ladd ME, Bachert P, Meyerspeer M et al (2018) Pros and cons of ultra-high-field MRI/MRS for human application. Prog Nucl Magn Reson Spectrosc 109:1&#x02013;50. 10.1016/j.pnmrs.2018.06.001<pub-id pub-id-type="pmid">30527132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cardenas</surname><given-names>AM</given-names></name><name><surname>Sarlls</surname><given-names>JE</given-names></name><name><surname>Kwan</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Pathology of callosal damage in ALS: an ex-vivo, 7 T diffusion tensor MRI study</article-title><source>Neuroimage Clin</source><year>2017</year><volume>15</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2017.04.024</pub-id><pub-id pub-id-type="pmid">28529876</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cardenas AM, Sarlls JE, Kwan JY et al (2017) Pathology of callosal damage in ALS: an ex-vivo, 7 T diffusion tensor MRI study. Neuroimage Clin 15:200&#x02013;208. 10.1016/j.nicl.2017.04.024<pub-id pub-id-type="pmid">28529876</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Donatelli</surname><given-names>G</given-names></name><name><surname>Emmi</surname><given-names>A</given-names></name><name><surname>Costagli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Brainstem anatomy with 7-T MRI: in vivo assessment and ex vivo comparison</article-title><source>Eur Radiol Exp</source><year>2023</year><volume>7</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s41747-023-00389-y</pub-id><pub-id pub-id-type="pmid">37968363</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Donatelli G, Emmi A, Costagli M et al (2023) Brainstem anatomy with 7-T MRI: in vivo assessment and ex vivo comparison. Eur Radiol Exp 7:71. 10.1186/s41747-023-00389-y<pub-id pub-id-type="pmid">37968363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Harteveld</surname><given-names>AA</given-names></name><name><surname>Denswil</surname><given-names>NP</given-names></name><name><surname>Siero</surname><given-names>JCW</given-names></name><etal/></person-group><article-title>Quantitative intracranial atherosclerotic plaque characterization at 7T MRI: an ex vivo study with histologic validation</article-title><source>AJNR Am J Neuroradiol</source><year>2016</year><volume>37</volume><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.3174/ajnr.a4628</pub-id><pub-id pub-id-type="pmid">26705320</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Harteveld AA, Denswil NP, Siero JCW et al (2016) Quantitative intracranial atherosclerotic plaque characterization at 7T MRI: an ex vivo study with histologic validation. AJNR Am J Neuroradiol 37:802&#x02013;810. 10.3174/ajnr.a4628<pub-id pub-id-type="pmid">26705320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Mankovich</surname><given-names>NJ</given-names></name><name><surname>Robertson</surname><given-names>DR</given-names></name><name><surname>Cheeseman</surname><given-names>AM</given-names></name></person-group><article-title>Three-dimensional image display in medicine</article-title><source>J Digit Imaging</source><year>1990</year><volume>3</volume><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/BF03170565</pub-id><pub-id pub-id-type="pmid">2092812</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mankovich NJ, Robertson DR, Cheeseman AM (1990) Three-dimensional image display in medicine. J Digit Imaging 3:69&#x02013;80. 10.1007/BF03170565<pub-id pub-id-type="pmid">2092812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>HA</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name></person-group><article-title>Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future</article-title><source>Clin Mol Hepatol</source><year>2023</year><volume>29</volume><fpage>S136</fpage><lpage>S149</lpage><pub-id pub-id-type="doi">10.3350/cmh.2022.0436</pub-id><pub-id pub-id-type="pmid">36503205</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yu JH, Lee HA, Kim SU (2023) Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol 29:S136&#x02013;S149. 10.3350/cmh.2022.0436<pub-id pub-id-type="pmid">36503205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ajmera</surname><given-names>V</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name></person-group><article-title>Imaging biomarkers of NAFLD, NASH, and fibrosis</article-title><source>Mol Metab</source><year>2021</year><volume>50</volume><fpage>101167</fpage><pub-id pub-id-type="doi">10.1016/j.molmet.2021.101167</pub-id><pub-id pub-id-type="pmid">33460786</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ajmera V, Loomba R (2021) Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 50:101167. 10.1016/j.molmet.2021.101167<pub-id pub-id-type="pmid">33460786</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>